PDCD1 and melanoma: The classic combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) has shown clinically meaningful successes in a variety of advanced solid tumors, including melanoma, NSCLC, HCC, renal cell carcinoma, and colorectal cancer15.